

**Remarks**

Prior to this supplemental amendment, claims 1-12 and 19-35 were pending in this application. Claims 1, 2, 7-12, 19, 29, 32, and 33 are amended herein. Claim 31 is canceled herein.

Claims 1, 2, 7-12, 29, and 33 are amended to correct matters of form. Claim 32 is amended to correct dependency. Support for the amendment of claims 1, 19, 29, and 33 can be found in the specification at least at page 54, lines 15-23 and at page 55, lines 4-6.

No new matter has been added by these amendments. Unless specifically stated otherwise, none of these amendments are intended to limit the scope of any claim. Applicants reserve the right to prosecute any removed subject matter in a continuation application. These amendments do not alter the remarks submitted with the response filed on November 13, 2007, other than to more clearly point out that Svendsen *et al.* does not specifically teach similar antimicrobial activity or increased polypeptide stability compared to the polypeptide of interest, wherein the arginine residue is ADP-ribosylated (see remarks related to claim rejections under §§102 and 103 in the response submitted on November 13, 2007).

After entry of this amendment, **claims 1-12, 19-30, and 32-35 are pending in this application.** Reconsideration of the pending claims is respectfully requested.

**Conclusion**

The claims are in condition for allowance and notification to this effect is requested. If for any reason the Examiner believes that a telephone conference would expedite allowance of the claims, please telephone the undersigned at the number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Anne Carlson/

Anne Carlson, Ph.D.

Registration No. 47,472